Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A-type kreotoxin B cell antigen epitope peptide and use thereof

A type A botulinum toxin and epitope technology, applied in the direction of receptors/cell surface antigens/cell surface determinants, specific peptides, material inspection products, etc., can solve the problem of restricting the development of botulinum toxin and unsuitable complex epitope research , labor cycle and other issues

Inactive Publication Date: 2007-08-15
MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these methods are time-consuming, laborious and require a long cycle, and are not suitable for the study of complex epitopes, thus restricting the development of botulinum toxin prevention research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A-type kreotoxin B cell antigen epitope peptide and use thereof
  • A-type kreotoxin B cell antigen epitope peptide and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Determination of Type A Botulinum Toxin Epitope Peptide

[0021] 1. Materials:

[0022] SEPHADEX G-15; SEPHAROSE affinity column; HPLC was purchased from Pharmacia;

[0023] Insight II software, SGI graphics workstation is the product of Neotrident company.

[0024] 2. Methods and results:

[0025] 1. Screening of botulinum toxin type A Hc fragment B cell epitope

[0026] In 1998, RC Stevens&DB Lacy obtained the crystal structure (PDBstructure: 3BTA, 2.3 Ȧ) of the double-chain type A botulinum toxin made up of 1285 amino acid residues through high-resolution multidimensional crystal X-ray diffraction spectrum analysis; the present invention utilizes the protein database PDB ( http: / / www.rcsb.org / pdb / home / home.do) in the three-dimensional crystal structure of botulinum toxin type A, using Insight II software and SGI graphics workstation to analyze the epitope of botulinum toxin type A B cell For analysis, select at least three consecutive amino acid residue...

Embodiment 2

[0032] Example 2 Epitope peptide immunological analysis and its application in identification of botulinum toxin serotype

[0033] 1. Materials:

[0034] Anti-botulinum toxin type A, B, E horse serum, enzyme-labeled rabbit anti-horse IgG (China Institute for the Control of Biological Products)

[0035] 2. Methods and results:

[0036] 1. ELISA analysis of specific binding of short epitope peptides to botulinum antitoxin type A horse serum

[0037] Epitope peptides 1#, 2# and 3# (10 μg / well) were coated on an enzyme-linked plate, the coating solution was NaHCO3 pH8.6, and BSA was used as a negative control, and coated overnight at 4°C. Remove the coating solution, add 100 μl 3% BSA (0.02mol / L PBS, prepared at pH 7.2) to block at 37°C for 1 hour, add anti-botulinum toxin type A horse serum (1:3000 dilution), 100 μl / well, 37°C Combine for 1 hour; wash with PBST (0.05% Tween 20); add enzyme-labeled rabbit anti-horse IgG (1:1000 dilution) 100 μl / well, incubate at room temperatur...

Embodiment 3

[0042] Example 3 Preparation of Epitope Peptide Vaccine and Its Immunoprotective Effect

[0043] 1. Materials:

[0044] Epitope peptide, prepared according to the above-mentioned embodiment;

[0045] BALB / C mice were purchased from the Experimental Animal Center of the Academy of Military Medical Sciences.

[0046] 2. Methods and results

[0047] 1. Preparation of single or multi-component epitope peptide vaccines

[0048] Single epitope peptide antigen: Epitope peptides 1#, 2# and 3# with a purity > 85% were dissolved in 0.02mol / LPBS pH7.2 respectively to prepare epitope peptide antigens with a concentration of 0.8mg / ml.

[0049] Multi-component epitope peptide antigen: epitope peptides 1#, 2# and 3# with a purity > 85%, mixed uniformly at a ratio of 1:1:1, dissolved in 0.02mol / L PBS pH7.2, and prepared as per The concentration of the epitope peptide is still the epitope peptide antigen of 0.8mg / ml.

[0050] Epitope peptide vaccines: single or multi-component epitope pep...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a cell antigen epitope peptide of A-typed botulism toxin B as core immune antigen, which is characterized by the following: protecting botulism toxin from infecting; identifying A-typed specific antibody of botulism toxin due to characteristic antigen mark; distinguishing A-type from other patterns in the serum; making the short peptide possess the same or similar function with full toxin antigen and recombinant toxin antigen without allergic reaction; overcoming the serum crossing problem among full toxin antigen or recombinant antigen; diagnosing the infection of botulism toxin to prepare new peptide vaccine; fitting for targeting and sieving botulism toxin resistant drug.

Description

technical field [0001] The present invention relates to a biotoxin B cell antigen epitope peptide, specifically relates to a botulinum toxin B cell antigen epitope peptide, and also relates to the application of the above antigen epitope peptide. Background technique [0002] Botulinum neurotoxin (Clostridium Botulinum Neurotoxins, BoNT, referred to as botulinum toxin) is an exotoxin produced by Clostridium botulinum under anaerobic conditions. Strong protein, wherein A, B, and E-type botulinum toxins are common types that cause human poisoning. Clinical observations show that A-type botulinum toxins can cause more serious symptoms and lead to higher mortality than other serotypes. [0003] The precursor of botulinum toxin type A is a non-toxic single-chain protein with a molecular weight of 150kD. It is toxic only after being cut by bacterial protease or in vitro protease into a double-chain form, that is, the light chain (L) and the heavy chain (H) pass through a Disulfid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/705G01N33/53
Inventor 王慧史晶荫俊包士中侯晓军蔡昆
Owner MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com